Deep, specialized knowledge and a passion for the patient
Highly experienced oncology team spanning every resource level. We have a team of seasoned and well-retained oncology experts who are dedicated to advancing oncology research and therapeutics—expertise that extends to every person who works on your trial.
Oncology Site Network for predictable start-up and performance. You want your trial to hit your first milestone; that begins by selecting the right sites. Our specialized network of qualified oncology sites carefully aligns site capabilities to protocol requirements. Each site brings expertise in all phases and indications of oncology trials, backed by a commitment to expedited study start-up and quality processes—and a track record of success.
Deep engagement from seasoned oncology CRAs. Clinical research associates (CRAs) are perhaps the most critical resource on your trial. That’s why Precision takes great care in hiring the most seasoned CRAs. With a 95% retention rate, we work hard to retain them, too. While larger CROs assign CRAs 4–5 trials at a time, our CRAs embed themselves in just 1 or 2 trials. They stay with you through every phase of the trial, becoming specialists in your trial and ambassadors of your sites, understanding your protocol, mitigating challenges—and, ultimately, ensuring the delivery of quality patient data.
A uniquely patient-centric methodology. When your study is focused on a small, highly targeted population, every patient is critical. We use our deep understanding of the patient and family mindset to address each individual need and concern, so patients stay in your trial and follow your protocols.
The regulatory skill to expedite your orphan drug designation. It takes a deep knowledge of the precise proof points regulators require—and how to establish clinical verification of those parameters—to streamline the ODD process. Our track record of 100% data acceptance across all orphan projects speaks for itself.
A pioneering technique that addresses the complex challenges of rare disease clinical trials. By working with patient advocacy groups and key opinion leaders, we ensure that trial protocols are realistic given any limitations of the target patient population; use advanced biostatistical approaches to address the realities of rare diseases; define prevalence at country and site levels; and apply our specialized knowledge to identify, recruit, screen, and monitor patients across a wide geography. Maybe that’s why we’ve won the ROAR Awards “Best Orphan Drug CRO” for 2 consecutive years.
Deep knowledge of biostatistics for rare and orphan disease research. With far smaller population sizes, rare disease clinical trials produce limited evidence relative to traditional clinical trials, affecting both trial design and statistical approaches. Superlative biostatistical data management and analytic expertise enables us to support your protocol review and study design, sample size determination, endpoint selection, randomization schedules, outcomes measures and other critical study aspects—serving as your biostatistical analysis partner.
Unparalleled education of healthcare providers, patients, and caregivers to get the right medicine to the right person. We efficiently build awareness and understanding of your rare disease among the full spectrum of interested parties, supporting short-term patient recruitment and developing long-term product demand.